1 s 239 +/- 90 versus 240 +/- 115 mEq/8 h with sulfisoxazole.

2 ole (TMP-SMX), 355 (32%) to sulfamethoxazole-sulfisoxazole, 312 (28%) to tetracycline, 19 (2%) to nal

3 -1) for sulfamethazine, 118.5 mug kg(-1) for sulfisoxazole and 104.1 mug kg(-1) for sulfadimethoxine.

4 -1) for sulfamethazine, 114.4 mug kg(-1) for sulfisoxazole and 94.7 mug kg(-1) for sulfadimethoxine,

5 rug resistance (streptomycin, spectinomycin, sulfisoxazole, and tetracycline [St Spc Su Tet]).

6 oramphenicol, streptomycin, sulfamethoxazole-sulfisoxazole, and tetracycline, including 49 Shigella f

7 o ampicillin, chloramphenicol, streptomycin, sulfisoxazole, and tetracycline.

8                                              Sulfisoxazole had modest effects on serum pharmacokineti

9                                Resistance to sulfisoxazole in 21.7% of strains and to trimethoprim-su

10 p., and the use of a disk diffusion test for sulfisoxazole is proposed as a check of the adequacy of

11                Ampicillin, furazolidone, and sulfisoxazole resistance of ETEC increased during the st

12  mg for furosemide alone and furosemide plus sulfisoxazole, respectively.

13                             Here we identify sulfisoxazole (SFX) as an inhibitor of small extracellul

14  resistant to trimethoprim-sulfamethoxazole, sulfisoxazole, streptomycin, and furazolidone increased

15 loramphenicol, nalidixic acid, streptomycin, sulfisoxazole, tetracycline, and trimethoprim-sulfametho

16 splacement from urinary protein binding with sulfisoxazole would restore response to 120 mg of furose